Form 8-K · Current Report · Filed 2024-01-08
Moderna Reports 2023 Financial Results and Provides Business Update
Moderna, Inc. announced preliminary financial results for the fiscal year ended December 31, 2023, reporting approximately $6.7 billion in product sales. The company also disclosed that its cash, cash equivalents, and investments exceeded $13 billion as of the year-end. Moderna provided an outlook for 2024, expecting $4 billion in product sales and anticipating a return to sales growth in 2025. The company also highlighted significant progress in its pipeline, with nine late-stage programs having anticipated milestones in 2024 and 2025.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-24-000004
- CIK
- 0001682852
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$111.12
Next session
-0.8%
Since filing
-50.7%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Exhibits (1)
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.